Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

This study has been completed.
Information provided by (Responsible Party):
AstraZeneca Identifier:
First received: July 8, 2009
Last updated: January 8, 2015
Last verified: December 2014
To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma

Condition Intervention Phase
Drug: AZD2644
Drug: Dacarbazine
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Double-blind, Randomised Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma

Resource links provided by NLM:

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • To assess the efficacy in terms of overall survival of AZD6244 in combination with dacarbazine, compared with dacarbazine alone, in first line patients with BRAF mutation positive advanced cutaneous or unknown primary melanoma [ Time Frame: Overall survival calculated as the interval from date of randomisation to date of patient death (any cause). Patients who have not died at final analysis, or who withdraw consent, will be censored at last date they were known to be alive. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • To further assess the efficacy in terms of-Alive and Progression Free at 6 months (APF6)- Progression Free Survival (PFS)- Objective Response Rate (ORR)- Duration of Response (DoR)- Change in tumour size at 12 weeks [ Time Frame: APF6, PFS, ORR, DoR, and change in tumour size at 12 weeks will be assessed using RECIST measurements. RECIST assessments to be carried out at baseline, week 12 and every 12 weeks thereafter relative to randomisation ] [ Designated as safety issue: No ]
  • To assess the safety and tolerability profile of AZD6244 in combination with dacarbazine [ Time Frame: At every visit (ie weekly for the first 6 weeks and then every 3 weeks) ] [ Designated as safety issue: Yes ]
  • To investigate the pharmacokinetics of AZD6244 [ Time Frame: At Day 1 and Day 22 ] [ Designated as safety issue: No ]

Enrollment: 385
Study Start Date: July 2009
Study Completion Date: November 2014
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
AZD6244 in combination with dacarbazine
Drug: AZD2644
oral capsules, 75mg twice daily
Drug: Dacarbazine
1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
Other Name: DTIC
Placebo Comparator: 2
Placebo in combination with dacarbazine
Drug: Dacarbazine
1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
Other Name: DTIC
Drug: Placebo


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histological or cytological confirmation of advanced (inoperable stage III and stage IV) cutaneous or unknown primary melanoma
  • Tumor sample confirmed as BRAF mutation positive

Exclusion Criteria:

  • Diagnosis of uveal or mucosal melanoma
  • Any prior Investigational therapy comprising inhibitors of Ras, Raf or MEK
  • Having received an investigational drug within 30 days of starting treatment, or have not recovered from side effects of an investigational drug
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00936221

  Hide Study Locations
United States, Colorado
Research Site
Aurora, Colorado, United States
United States, Massachusetts
Research Site
Boston, Massachusetts, United States
Research Site
Belo Horizonte, Brazil
Research Site
Ijuí, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Sao Paulo, Brazil
Czech Republic
Research Site
Brno, Czech Republic
Research Site
Novy Jicin, Czech Republic
Research Site
Praha 2, Czech Republic
Research Site
Lille Cedex, France
Research Site
Marseille, France
Research Site
Villejuif Cedex, France
Research Site
Berlin, Germany
Research Site
Essen, Germany
Research Site
Hannover, Germany
Research Site
Kiel, Germany
Research Site
Tübingen, Germany
Research Site
Budapest, Hungary
Research Site
Györ, Hungary
Research Site
Székesfehérvár, Hungary
Research Site
Amsterdam, Netherlands
Research Site
Nijmegen, Netherlands
Research Site
Oslo, Norway
Research Site
Barcelona, Spain
Research Site
Houston, Spain
Research Site
Málaga, Spain
Research Site
Palma de Mallorca, Spain
Research Site
Göteborg, Sweden
Research Site
Malmö, Sweden
Research Site
Stockholm, Sweden
Research Site
Zürich, Switzerland
United Kingdom
Research Site
Cambridge, United Kingdom
Research Site
Chelmsford, United Kingdom
Research Site
London, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Newcastle upon Tyne, United Kingdom
Research Site
Oxford, United Kingdom
Research Site
Surrey, United Kingdom
Sponsors and Collaborators
Principal Investigator: Mark Middleton, Dr Churchil Hospital, Oxford, UK
Principal Investigator: Caroline Robert, Dr Institute Gustave Roussy, France
Study Director: Ian Smith, Dr AstraZeneca, Alderley Park, UK
  More Information

Additional Information:
No publications provided by AstraZeneca

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: AstraZeneca Identifier: NCT00936221     History of Changes
Other Study ID Numbers: D1532C00006
Study First Received: July 8, 2009
Last Updated: January 8, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by AstraZeneca:
BRAF mutation positive
advanced melanoma
Advanced cutaneous melanoma
Unknown primary melanoma

Additional relevant MeSH terms:
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas processed this record on November 27, 2015